Edoxaban in Peripheral Arterial Disease

Inclusion Criteria: * Male or female subjects older than the minimum legal adult age (country specific); * Rutherford stages 2-5 provided there are no ulcerations on the heel and/or exposed tendon and/or bone; * Superficial femoral above knee-popliteal ( 3 cm proximal to the medial femoral condyle) lesion and ≥ 50% stenosis or occlusion; * At least one run-off vessel to the foot with or without additional endovascular intervention; * Successful intervention, defined as angiographic confirmation of ≤ 30% residual stenosis and absence of flow limiting dissection; * Adequate hemostasis at the vascular access site within 24 hours of intervention; * A subject is also eligible if they have undergone additional successful endovascular intervention(s) during the index intervention; * Able to provide signed informed consent. Exclusion Criteria: * Calculated Creatinine Clearance \< 30 ml/min; * Femoral or popliteal aneurysm; * Adjunctive use of thrombolytics; * Any extravasation or distal embolization not successfully treated; * Uncontrolled hypertension as judged by the investigator (e.g., systolic blood pressure \> 170 mmHg or diastolic blood pressure \> 100 mmHg despite antihypertensives); * Aspirin intolerance; * Clopidogrel intolerance; * Contraindication for anticoagulants or antiplatelets and any other contraindication listed in the local labeling of aspirin and/or clopidogrel; * Active bleeding or known high risk for bleeding or history of intracranial, or spontaneous intraocular, spinal retroperitoneal or intra-articular bleeding; overt gastrointestinal (GI) bleeding or active ulcer within the previous year; * Subjects receiving dual antiplatelet or anticoagulant therapy at the time of randomization; subjects receiving pre-interventional loading dose of clopidogrel or other P2Y12 receptor antagonists; * Treatment with cilostazol within 24 hours of randomization; * Subjects receiving prohibited concomitant medications \[fibrinolytics, chronic use of non steroidal anti-inflammatory drugs (NSAIDS) \> 4 days per week, and oral or parenteral non-aspirin NSAIDs and strong P-gp inhibitors\]; * Prior stroke or myocardial infarction (MI) or acute coronary syndrome within 3 months; * Chronic liver disease \[alanine transaminase (ALT) and/or aspartate transaminase (AST) ≥ 2 × upper limit of normal; total bilirubin (TBL) ≥ 1.5 × upper limit of normal\]; however, subjects whose elevated TBL is due to known Gilbert"s syndrome may be included in the study; * Prior history of a positive test for Hepatitis B antigen or Hepatitis C antibody; * Subjects who received any investigational drug or device within 30 days prior to randomization, or plan to receive such investigational therapy during the study period; * Subjects previously randomized to an edoxaban (DU-176b) study; * Women of childbearing potential without proper contraceptive measures (i.e. a method of contraception with a failure rate \< 1 % during the course of the study including the observational period) and women who are pregnant or breast feeding; * Subjects with the following diagnoses or situations: Active malignancy except for adequately treated non-melanoma skin cancer or other non-invasive or in-situ neoplasm (e.g., cervical cancer in situ); Concurrent treatment with cancer therapy (drugs, radiation, and/or surgery); Other significant active concurrent medical illness or infection; Life expectancy \< 12 months; * Subjects who are unlikely to comply with the protocol (e.g., uncooperative attitude, inability to return for subsequent visits, and/or otherwise considered by the Investigator to be unlikely to complete the study); * Subjects with any condition that, in the opinion of the Investigator, would place the subject at increased risk of harm if he/she participated in the study; * History of heparin-induced thrombocytopenia